avatar Regeneron Pharmaceuticals Inc Manufacturing
  • Location: New York 
  • Founded:
  • Website:

Pages

  • Page 1

    ANNUAL REPORT G R OWT H T H R O U G H I N N O VAT I O N MENU >


  • Page 2

    CONTENTS 3 REGENERON AT A GL ANCE 4 SHAREHOLDER LE T TER 7 MARK E TED PRODUC TS 12 L ATE-STAGE PIPELINE 15 ADDITIONA L PIPELINE PROGR AMS 20 GROW TH 22 CITIZENSHIP 28 FORWARD-LOOK ING STATEMENTS 29 CORPOR ATE INFORMATION 30 REFERENCES


  • Page 3

    REGENERON AT A GLANCE < < M ENMENU U > > 2016 ANNUAL REPORT 3


  • Page 4

    DEAR FELLOW SHAREHOLDERS, In 2016, we reaffirmed our core strategy of growth through innovation and continued to advance our mission of consistently and repeatedly bringing important new medicines to patients in need. Turning science into important drugs is one of the most difficult activities Turning to our currently marketed medicines, we continue to bring EYLEA ® an organization can undertake. Despite thousands of biopharmaceutical (aflibercept) Injection, our market-leading therapy for the treatment of serious companies in the United States and billions in R&D spend, only 22 novel vision-threatening diseases, to more and more indicated patients. In 2016, drugs were approved by the U.S. Food and Drug Administration (FDA) in EYLEA global net sales were $5.2 billion, including $3.3 billion in U.S. net 2016. Of these, only eight were first in class, and even fewer targeted sales. We continue to work to improve outcomes in serious retinal diseases major diseases affecting millions of people. With this background, it is quite and have an ongoing Phase 3 trial with EYLEA in diabetic retinopathy, as well a testament to the Regeneron team that, by the end of 2017, we anticipate as a combination program evaluating EYLEA co-formulated with nesvacumab, having five new medicines approved since 2011, all of which are first- or an investigational ANG-2 antibody. second-in-class therapies. Praluent® (alirocumab) Injection, our therapy for uncontrolled LDL cholesterol, We laid important groundwork last year that has positioned us for a demonstrated gradual sales growth in 2016, reaching $116 million in global potentially transformational year in 2017, with two important new drug net sales. This growth was hampered by significant launches. Dupixent® (dupilumab) Injection was approved on March 28, access challenges and a desire from payers 2017, by the FDA and the launch is ongoing. Moderate-to-severe atopic and physicians to see positive dermatitis is a serious inflammatory disease with limited treatment options. outcomes data. We expect to Patients suffer with widespread rash, debilitating itching, and other complete our 18,000-patient challenges. We believe Dupixent, which the FDA had designated a ODYSSEY OUTCOMES By the end of 2017, Breakthrough Therapy, represents an important scientific advance and, study by the end of 2017. Together with our we anticipate having five most importantly, new hope for patients in need. We also recently resubmitted our U.S. application for Kevzara® (sarilumab) for the treatment collaborators at Sanofi, new medicines approved of moderately to severely active rheumatoid arthritis, and expect an FDA we continue to since 2011, all of which are first- decision later in 2017. defend our position or second-in-class therapies. < < M ENMENU U > > 2016 ANNUAL REPORT 4


  • Page 5

    in the ongoing patent litigation related to Praluent. We believe the controlling We also have a late-stage program ongoing for fasinumab, our antibody to law and facts support our position and look forward to a timely resolution of Nerve Growth Factor (NGF) for osteoarthritis pain and chronic lower back this matter. pain, and in 2016, we entered a major new global collaboration with Teva for the development of this product candidate, which will help us advance this Our pipeline continues to grow with potential innovations across a number program. Our late-stage pipeline is rounded out with suptavumab, our of serious diseases. Dupilumab, in particular, has the potential to represent antibody to respiratory syncytial virus (RSV), a serious respiratory infection in a pipeline in a single compound as the therapy targets a key signaling infants, and our PD-1 antibody, REGN2810, for the treatment of non-small cell pathway that is believed to drive a number of allergic diseases. We expect lung cancer (NSCLC) and a serious skin cancer. top-line Phase 3 results for dupilumab in patients with asthma, followed by a potential U.S. regulatory submission in this indication by year-end 2017. We Our early-to-mid-stage programs also continue to make important progress. are also studying dupilumab in late-stage trials of patients with nasal polyps, Programs include evinacumab, our Angptl-3 antibody for homozygous familial pediatric asthma, and pediatric atopic dermatitis, in addition to earlier-stage hypercholesterolemia, an inherited lipid disorder; additional immuno-oncology studies in eosinophilic esophagitis. candidates, including a bi-specific antibody for blood cancers; and an Activin A antibody for a rare and extremely serious disease known as Fibrodysplasia Ossificans Progressiva. We continue to prioritize ongoing investment in technology and innovation, which we believe will position us to bring needed new medicines to patients for many years to come. One of these efforts is the Regeneron Genetics Center We continue to prioritize (RGC), which in just a little over three years after launch has sequenced more than 150,000 consented individuals. In March 2017, the RGC embarked on an ongoing investment in technology important collaboration in the United Kingdom with the goal of sequencing all and innovation, which we believe will the participants in the UK Biobank, the world’s most comprehensive position us to bring needed new medicines health resource, which includes samples and medical records from to patients for many years to come. 500,000 volunteer participants. Importantly, the RGC efforts have already identified exciting new targets for drug development. < < M ENMENU U > > 2016 ANNUAL REPORT 5


  • Page 6

    As we have grown to employ over 5,500 people, we have also grown physically — commitment to support this program, which plays a critical role in the we continue to expand our manufacturing facilities in Rensselaer, New York, and development of a strong science talent pipeline for generations to come and in Raheen, Ireland, and we also purchased an office building near our Tarrytown, elevating the place of science in our society. New York facility, which will help expand the footprint of our headquarters in Westchester County, New York. Also, in early 2017, we completed a new lease We invite you to read about our 2016 accomplishments, financial performance financing for our Tarrytown corporate headquarters. As a result of this and corporate citizenship efforts in our online annual report and in our 2016 transaction, we have obtained an option to buy the facility at the end of the Annual Report on Form 10-K, which are available on the Investor Relations five-year lease term and are poised to benefit from immediate cash savings and portion of our website. increased flexibility for future growth. We are very much looking forward to a successful 2017 and continuing to deliver Finally, in 2016, we were thrilled to expand our long-standing dedication to on our mission of developing transformative medicines for patients. science education with a major philanthropic commitment to inspire future innovators. We became only the third sponsor in 75 years of the nation’s oldest and most prestigious high school science competition, now known as the Sincerely, Regeneron Science Talent Search. This program was previously sponsored by Intel, and before that, by Westinghouse. We have made a 10-year, $100 million Len, George, and Roy Leonard S. Schleifer, MD, PhD George D. Yancopoulos, MD, PhD P. Roy Vagelos, MD President and Chief Executive Officer President and Chief Scientific Officer Chairman of the Board < < M ENMENU U > > 2016 ANNUAL REPORT 6


  • Page 7

    MARKETED P R O D U CTS M A K E G R E AT M E D I C I N E THEN DO IT AGAIN AND AGAIN < < M ENMENU U > > 2016 ANNUAL REPORT 7


  • Page 8

    EYLEA® (AFLIBERCEPT) INJECTION AND RETINAL DISEASE PROGRAMS Market-leading anti-VEGF approved in more than 100 countries for the treatment of key blindness-causing retinal conditions including wet age-related macular degeneration (AMD) and diabetic macular edema (DME). EYLEA global net sales exceeded $5 billion in 2016. In the United States, EYLEA net sales increased EYLEA U.S. SALES: 24% INCREASE 24% to $3.32 billion for the full year 2016 from $2.68 billion for the full year 2015. Outside of the United $3.32 bn States, where our collaborator Bayer HealthCare commercializes EYLEA, net sales were $1.87 billion in $2.68 bn 2016, compared to $1.41 billion in 2015. Regeneron recognized $649 million from its share of net profit outside the United States in 2016, compared to $467 million in 2015. $1.74 bn “We’re proud that EYLEA has helped many patients over the last several years. We continue to work on new innovations for people with serious vision-threatening diseases in an effort to further 2014 2015 2016 improve outcomes for these patients.” — Robert L. Vitti, MD, Vice President and Head of Ophthalmology EYLEA EX-U.S. SALES: 33% INCREASE $1.87 bn $1.41 bn $1.04 bn In 2017, we continue to enroll patients in our ongoing Phase 3 study of EYLEA in non-proliferative diabetic retinopathy, a common eye disease that impacts many people with diabetes. In addition to this new indication, we are exploring EYLEA in combination with nesvacumab, an anti-angiopoietin 2 antibody, in two fully enrolled Phase 2 trials — RUBY in DME and ONYX in wet AMD. In 2016, we discontinued the development of another EYLEA combination therapy, aflibercept + rinucumab, an anti–platelet-derived growth factor receptor beta (anti-PDGFR-beta) 2014 2015 2016 antibody, which did not demonstrate improvement in best corrected visual acuity (BCVA) compared to aflibercept Sales increases represent year-over-year growth from 2015 to 2016. monotherapy in our Phase 2 CAPELLA study. Though pre-clinical data for the co-formulation of aflibercept and nesvacumab are more supportive, EYLEA sets a very high efficacy bar in the treatment of these disease indications. < < M ENMENU U > > 2016 ANNUAL REPORT 8


  • Page 9

    PRALUENT® (ALIROCUMAB) INJECTION Monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) available in two doses, allowing for dose adjustment based on patients’ LDL-C–lowering needs. “After I suffered a major Praluent completed its first full year on the market in 2016, with $116 million in global net sales. Praluent is a PCSK9 inhibitor approved by the FDA as adjunct to diet and maximally tolerated statin therapy for the heart attack and was at treatment of heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease risk for another one, I in adults who require additional lowering of LDL-C (often referred to as “bad cholesterol”). The effect of was afraid I would not Praluent on cardiovascular morbidity and mortality has not been determined. be here for the future of The ongoing ODYSSEY OUTCOMES clinical trial program, which is evaluating the potential of Praluent to my two children. Now prevent heart attacks, stroke and cardiac death, reached full enrollment in 2015, with more than 18,000 patients that my bad cholesterol at over 2,000 study centers. Two prespecified interim analyses were performed by an independent Data is under control, I feel Monitoring Committee in 2016 — the first, a futility analysis when 50% of cardiovascular events had occurred, and the second analysis, for both futility and overwhelming efficacy, when 75% of cardiovascular events had occurred. like I have my life back!” The trial continued as planned following both analyses, and we expect to complete the study in late 2017. — Peggy, We continue to be involved in patent litigation with Amgen related to Praluent. In 2016, a District Court jury ruled Praluent patient against us, upholding the validity of Amgen’s patents. In early 2017, the District Court granted a permanent injunction requested by Amgen, preventing the marketing, selling, or commercial manufacturing of Praluent in the United States. We have appealed both of these decisions to the U.S. Court of Appeals for the Federal Circuit, which hears all biopharmaceutical patent litigation appeals, and the court has stayed (suspended) the permanent injunction for Praluent that was granted by the District Court, pending appeal. This stay ensures that Praluent will continue to be available to patients during the ongoing appeal process. We strongly believe that the controlling law and facts support our position that Amgen’s asserted patent claims are invalid. We look forward to pursuing our appeal over the coming months. < < M ENMENU U > > 2016 ANNUAL REPORT 9


  • Page 10

    DUPIXENT® (DUPILUMAB) INJECTION First-in-class monoclonal antibody that treats moderate-to-severe atopic dermatitis (AD) by blocking IL-4 and IL-13, two key cytokines involved in allergic diseases. Dupixent has been approved in the United States and is under regulatory review in the European Union for the treatment of atopic dermatitis (AD). It is also being studied in other allergic conditions including asthma, nasal polyps, and eosinophilic esophagitis. “I so appreciate all In March of 2017, Dupixent was approved by the FDA for the treatment of moderate-to-severe AD in adults whose disease is not adequately controlled with topical prescription therapies or for whom those therapies are not advisable. Dupixent can be used with the researchers or without topical corticosteroids. With our collaborator Sanofi, we launched the product to the commercial market shortly following who worked on approval. We are excited to provide this first-in-class medicine to adult patients who, up until the approval of Dupixent, had no bringing Dupixent FDA-approved biologic therapies to treat their uncontrolled moderate-to-severe AD. Additionally, in December of 2016, the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for Dupixent for the treatment of to atopic dermatitis moderate-to-severe AD in adults who are candidates for systemic therapy. We expect a decision from the EMA later in 2017. patients like me. In 2016, we reported positive data from three Phase 3 trials of Dupixent (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, and LIBERTY I now feel AD CHRONOS) in adult patients with moderate-to-severe AD. In these studies, treatment with Dupixent as monotherapy or as confident spending concomitant treatment with topical medications significantly improved measures of overall disease severity, skin clearing, and itching. time with my family, We are also studying dupilumab in pediatric patients with moderate-to-severe AD, and have been granted Breakthrough Therapy continuing my designation by the FDA for a subset of pediatric patients with moderate-to-severe AD. We began a Phase 3 trial in adolescents music career and (aged 12 to 17 years) with moderate-to-severe AD in the first quarter of 2017, and we expect to initiate a trial in children (aged 6 to 11 years) with severe AD later in 2017. living my life to the fullest.” Our second pivotal study for the treatment of asthma, LIBERTY ASTHMA QUEST, is fully enrolled, with data expected in the second half of 2017. We plan to submit a U.S. regulatory filing for dupilumab in this indication by year-end 2017. In the second quarter of 2017, — Lisa, harpist and we anticipate beginning enrollment of a Phase 3 trial in uncontrolled, persistent asthma in children (aged 6 to 11 years). Dupixent patient Progress continues on our other indications as well. We have begun enrolling patients with nasal polyps in two Phase 3 trials, and expect to begin enrolling patients with food allergies in a Phase 2 trial in the second half of 2017. We also expect Phase 2 data from our ongoing trial in patients with eosinophilic esophagitis in the second half of 2017. < < M ENMENU U > > 2016 ANNUAL REPORT 10


  • Page 11

    KEVZARA® (SARILUMAB) INJECTION IL-6R antibody under U.S. and EU regulatory review for the treatment of rheumatoid arthritis (RA). Kevzara has been approved in Canada. In 2016, we reported positive data from the Phase 3 SARIL-RA-MONARCH monotherapy “RA impacts every aspect of study, which met its primary endpoint by demonstrating that Kevzara was superior to my life and when its Humira® (adalimumab) in improving signs and symptoms in adults with active RA who were inadequate responders to, intolerant of, or inappropriate candidates for methotrexate. uncontrolled it makes me feel It was the first time a subcutaneously delivered IL-6 receptor blocker demonstrated like I can’t do anything I love. superiority over adalimumab monotherapy in RA. I’m so glad people continue In 2016, the EMA accepted for review the MAA for sarilumab, and an application for marketing to develop new treatments so approval for sarilumab was submitted in Japan. In the United States, we, along with our collaborator Sanofi, submitted the U.S. Biologics License Application (BLA) for Kevzara in I can go back to doing the November 2015, and were assigned a Prescription Drug User Fee Act (PDUFA) date of things I love – playing with my October 30, 2016. On October 28, 2016, we received a Complete Response Letter (CRL) from the FDA related to a Sanofi manufacturing facility. In early 2017, after the facility completed a five grandchildren, quilting, successful FDA re-inspection, we resubmitted the Kevzara BLA. We expect an FDA decision in and cooking.” the second quarter of 2017. Finally, in February 2017, Kevzara received approval and was launched in the commercial market in Canada for the treatment of moderately to severely — Michelle, seamstress and active RA in adults who have had an inadequate response or intolerance to one or more RA clinical trial patient biologic or non-biologic disease-modifying antirheumatic drugs (DMARDs). < < M ENMENU U > > 2016 ANNUAL REPORT 11


  • Page 12

    LAT E - STA G E PIPELINE N E V E R STO P ASKING WHY < < M ENMENU U > > 2016 ANNUAL REPORT 12


  • Page 13

    PIPELINE (as of April 2017) Regeneron has fifteen fully human monoclonal antibodies in clinical development that were developed using our proprietary VelocImmune ® technology. PHASE 1 PHASE 2 PHASE 3 REGN1908-1909 TREVOGRUMAB DUPILUMAB* NESVACUMAB + ALIROCUMAB* AFLIBERCEPT Feld1 Antibody GDF8 Antibody IL-4R Antibody AFLIBERCEPT^ PCSK9 Antibody VEGF-Trap Allergic disease (in combination Eosinophilic esophagitis Ang2 Antibody + Hypercholesterolemia Diabetic retinopathy with REGN2477) Aflibercept without diabetic REGN2810* SARILUMAB* Wet age-related SARILUMAB* macular edema PD-1 Antibody REGN2477 IL-6R Antibody macular degeneration, IL-6R Antibody Cancer Activin A Antibody Juvenile idiopathic diabetic macular Rheumatoid arthritis SUPTAVUMAB Fibrodysplasia arthritis edema RSV Antibody REGN1979 ossificans progressiva DUPILUMAB* Respiratory syncytial CD20XCD3 Antibody (also in combination EVINACUMAB REGN2810* IL-4R Antibody virus infection Cancer with trevogrumab) Angptl3 Antibody PD-1 Antibody Atopic dermatitis in (also in combination Homozygous familial Advanced children, asthma in FASINUMAB † with REGN2810) REGN3500* cutaneous squamous NGF Antibody hypercholesterolemia adults and children, Pain due to IL-33 Antibody cell carcinoma nasal polyps osteoarthritis REGN3470-3471-3479 Inflammatory diseases FASINUMAB † Antibody to Ebola virus NGF Antibody Ebola virus infection REGN3767* Pain due to chronic LAG-3 Antibody lower back pain Cancer (also in combination with REGN2810) * in collaboration with Sanofi ^ in collaboration with Bayer HealthCare ex-U.S. † in collaboration with Mitsubishi Tanabe Pharma Corporation (Asia) and Teva < < M ENMENU U > > 2016 ANNUAL REPORT 13


  • Page 14

    SUPTAVUMAB “An RSV infection can be serious and very frightening for parents of infants and young children — we’re evaluating Fully human monoclonal antibody being investigated for a therapeutic candidate to see if it has the prevention of serious lower respiratory tract infections the potential to prevent these associated with respiratory syncytial virus (RSV). infections before they start.” In 2016, we continued enrollment of the Phase 3 NURSERY-preterm trial that is evaluating the efficacy, safety, — Leah Lipsich, PhD, Vice President, pharmacokinetics (PK) and immunogenicity of suptavumab in infants born at a gestational age of 35 weeks or Strategic Program Direction less who are younger than 6 months. We expect to report topline data from this trial in the second half of 2017. FASINUMAB Nerve growth factor–targeting antibody being evaluated for novel, non-opioid approach to certain chronic pain conditions. OA affects more than In 2016, we announced a global collaboration to develop and commercialize fasinumab with Teva, a leading global pharmaceutical company with expertise in pain therapeutics. Under a previously announced collaboration 30 MILLION adults in agreement with Regeneron, Mitsubishi Tanabe Pharma Corporation (MTPC) has exclusive development and commercial rights to fasinumab in Japan, Korea, and nine other Asian countries. We believe both Teva and 80 % the U.S.1 MTPC will be strong partners in potentially bringing fasinumab to the market and those patients in need. of people with OA report some degree We launched a large Phase 3 clinical program studying fasinumab for pain due to osteoarthritis (OA) in 2016 of movement and continue to enroll patients. The FDA placed our Phase 2 trial in chronic lower back pain (CLBP) on hold limitation 2 Back pain is the in the fourth quarter of 2016, following the observation of a case of rapidly progressing OA in a patient who was receiving high-dose fasinumab and had a history of advanced OA of the knee. This event prompted MOST COMMON an unplanned interim analysis of the study, which had completed 70% of its targeted enrollment and type of pain among *Includes low back pain, showed clear evidence of efficacy and improvement in pain scores for all dosing groups. Following severe headache or adults in the U.S. 3* migraine and neck pain. communications with the FDA, we plan to continue development of fasinumab in CLBP without advanced OA. In collaboration with Teva, we expect to initiate a Phase 3 trial in 2017. < < M ENMENU U > > 2016 ANNUAL REPORT 14


  • Page 15

    ADDITIONAL PIPELINE PROGRAMS O U R G R E AT E ST D I S C O V E R I E S H AV E Y E T TO B E D E F I N E D < < M ENMENU U > > 2016 ANNUAL REPORT 15


  • Page 16

    IMMUNO-ONCOLOGY Our portfolio in this rapidly developing field grew in 2016, through both new product candidates and new indications for existing candidates, supported by our ongoing collaboration with Sanofi. Our growing clinical-stage immuno-oncology pipeline now includes three antibodies: a PD-1 inhibitor, a CD20xCD3 bi-specific antibody, and an antibody to LAG3. In 2016, we presented Phase 1 data from our PD-1 program, which helped us determine the therapeutic dose for our ongoing, potentially pivotal Phase 2 trial in cutaneous squamous cell carcinoma. This study is currently enrolling patients. In 2017, we plan to initiate a Phase 3 study in non-small cell lung cancer, as well as a potentially pivotal study in basal cell carcinoma. We also presented interim data from our CD20xCD3 bi-specific program in 2016. The CD20xCD3 antibody is currently in clinical trials both as a monotherapy and as a combination therapy with our PD-1 antibody. We are also conducting studies of REGN3767, our antibody to LAG3, both as a monotherapy and as a combination therapy with our PD-1 antibody. A number of additional immuno-oncology antibodies are expected to enter the clinic in 2017 and 2018, and we continue to pursue business development opportunities with novel immuno-oncology approaches that have potential to be combined with antibodies. < < M ENMENU U > > 2016 ANNUAL REPORT 16


  • Page 17

    RARE DISEASES We are expanding our research into rare diseases, where serious unmet medical needs provide the opportunity to deliver on our mission of turning science into life-changing medicine. Our most clinically advanced rare disease antibody, evinacumab, an antibody to Angptl-3, is in clinical development for the treatment of homozygous familial hypercholesterolemia (HoFH), which is the most severe form of hypercholesterolemia. Patients with this disease are at a significantly higher risk of serious cardiac events, including heart attack and stroke. In the first half of 2016, we presented positive interim data from a Phase 2 proof-of-concept study of evinacumab in patients with HoFH. We also entered REGN2477, our antibody to Activin A, into clinical development for the treatment of fibroplasia ossificans progressiva (FOP). FOP is a progressive, severely disabling, and ultimately fatal disease in which muscles, ligaments, tendons, and other connective tissues are transformed into bone. We entered the drug into a Phase 1 study in healthy volunteers in 2016, and expect to move into a Phase 2 trial in 2017. We also initiated a Phase 1 study of REGN2477 in combination with REGN1033, our antibody to GDF8, in 2016. REGN2477 has been granted orphan drug designation status by the FDA. In pre-clinical development we have a number of indications and programs identified, including transthyretin-related amyloidosis (TTR), juvenile X-Linked retinoschisis, and a C5 complement inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). We are working to advance these programs further in 2017. < < M ENMENU U > > 2016 ANNUAL REPORT 17


  • Page 18

    RAPID RESPONSE + INFECTIOUS DISEASE Regeneron’s rapid response capabilities leverage our core VelociSuite ® technologies to significantly compress the time required for discovery and pre-clinical validation of potential treatments for emerging infectious diseases. In 2016, work continued on our antibodies to the Ebola virus (REGN3470-3471-3479), where we began a Phase 1 study in healthy volunteers in the first half of 2016, and the antibody was granted orphan designation status by the FDA. This program is in development with the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services. In pre-clinical development, we also have antibodies to Middle Eastern respiratory virus (MERS) and the Zika virus. < < M ENMENU U > > 2016 ANNUAL REPORT 18


  • Page 19

    REGENERON GENETICS CENTER The Regeneron Genetics Center (RGC) is one of the world’s largest genetic sequencing initiatives, providing important insights into target identification and clinical development. The Regeneron Genetics Center (RGC) is a leader in human genetics research. Our RGC scientists have sequenced more than 150,000 consented individuals, entered into more than 30 academic collaborations, and have continuously supported our clinical development efforts. We expect these efforts to help us discover new targets, indications and biomarkers that could better predict drug response, and help de-risk the process of bringing new medicines into the clinic. We ended 2016 with two simultaneous publications in Science, one of which provided the first overall description of the Geisinger-Regeneron Genetics Center (RGC) collaboration known as DiscovEHR, and the other demonstrated the underdiagnosis and undertreatment of familial hypercholesterolemia (FH) through pairing genetic variants causing FH with their de-identified medical histories. In March 2017, we announced a major new RGC initiative with UK Biobank and GSK, in which we will be sequencing 500,000 individuals in the UK Biobank’s health resource. We expect new and important publications and continued RGC progress in 2017. < < M ENMENU U > > 2016 ANNUAL REPORT 19


  • Page 20

    G R OWT H BE AN ENGINE OF INVENTION < < M ENMENU U > > 2016 ANNUAL REPORT 20


  • Page 21

    GROWTH Be an engine of invention. In 2016, we continued to grow, adding both employees and other important assets. As a result of this transaction, we have obtained an option to buy the facility at the Our manufacturing facilities in Rensselaer and Raheen both grew — in Rensselaer end of the five-year lease term and are poised to benefit from immediate cash we expanded our product manufacturing operations, and in Raheen we continued savings and increased flexibility for future growth. Finally, we welcomed our 5,000th construction and hired new employees for the site. We also expanded our Regeneron employee in 2016. Each employee helps us continually deliver on our headquarters, purchasing an office building near our Tarrytown facility, and in early mission to help patients with serious diseases, and reminds us that our people are 2017, we completed new lease financing for our Tarrytown corporate headquarters. what make Regeneron great. REVENUE FULL-TIME EMPLOYEES R&D INVESTMENT † $4.860 bn 5,400* $2.052 bn $4.104 bn 4,300 $1.621 bn $1.271 bn $2.820 bn 18 % 2,925 26 % 27 % increase increase increase 2014 2015 2016 2014 2015 2016 2014 2015 2016 † *700 hold a PhD and/or Generally Accepted Accounting MD or PharmD degree. Principles R&D Expenses < < M ENMENU U > > 2016 ANNUAL REPORT 21


  • Page 22

    CITIZENSHIP MAKING A DIFFERENCE B E YO N D O U R LA B S < < M ENMENU U > > 2016 ANNUAL REPORT 22


  • Page 23

    FOCUSED ON CREATING A BETTER TOMORROW In addition to our dedication to patients and the development of life-transforming medicines, we are committed across the organization to our four pillars of citizenship: FOSTERING CULTIVATING SUPPORTING NURTURING the future of sustainable patient our high-engagement scientific innovation communities communities high-integrity culture < < M ENMENU U > > 2016 ANNUAL REPORT 23


  • Page 24

    FOSTERING THE FUTURE OF SCIENTIFIC INNOVATION We believe in future scientists’ power to advance societal progress, solve our most pressing global challenges, and create a healthier tomorrow. 2,190 hours of teacher development REGENERON SCIENCE TALENT SEARCH In 2016, Regeneron became the new sponsor of the Science Talent Search (STS), a program of the Society for Science & the Public, and our nation’s most prestigious science and math competition for high school seniors. This 76-year-old program was previously sponsored by 4,000 high school subscriptions Westinghouse and then by Intel. We made a 10-year, $100-million commitment, and nearly to Science News doubled the competition’s overall award distribution to $3.1 million annually. We are committed to expanding and diversifying the Science Technology Engineering and Math (STEM) talent pool, and have consequently earmarked $30 million for Society programs aiming to increase access to STEM education and resources for underrepresented populations. WESTINGHOUSE (1942-1998) 298 INTEL (1998-2016) Regeneron interns In addition to the Regeneron STS, we focus our STEM education efforts across three areas of impact: ~1,700 Regeneron STS entrants ATTRACTING EXCELLENCE WIDENING THE POOL AMPLIFYING A MOVEMENT Progress thrives when the brightest minds go into Recruiting a more diverse STEM workforce starts with awareness and equity. We focus As a company founded with the goal of transforming lives through 4,062 science. We support these on capacity-building programs that bridge science, we are committed to hours of science sharp young students by access to quality science education and promoting the important role of instruction aboard the funding programs such as the address systemic change in science science in our society. We are BioBus (made possible Regeneron-Westchester instruction. The BioBus, STEM Teaching sharing our deep commitment to by Regeneron funding) Science and Engineering Fair, Fellowship and Science News in High science education and leading a Regeneron Prize for Creative Schools are just a few of the ways we drive movement to drive greater Innovation and high school deeper interest in science, support collective action across our industry, research mentorship programs. scientific literacy, and facilitate discovery. communities, and country. < < M ENMENU U > > 2016 ANNUAL REPORT 24


  • Page 25

    CULTIVATING SUSTAINABLE COMMUNITIES We proudly expand on our mission to improve human life with our efforts to strengthen our communities through environmental and social action. COMMUNITY INVOLVEMENT ENVIRONMENTAL SUSTAINABILITY At Regeneron, volunteering is an essential part of the employee experience. As we continue to grow, environmental stewardship and responsible growth remain We empower our people to give back and create meaningful change in our at our core. In 2013, we set five-year targets in four major focus areas to communities through Regeneron In the Community, our company volunteer measure and monitor our environmental progress. With just two years remaining, program. Not only do our employees donate their time, talent and leadership to we are on track to meet or exceed each of these goals. With our evolving global help tackle some of our communities’ most pressing problems, but their collaborations and new product development efforts, we remain committed to involvement also inspires communal action. monitoring and reducing the environmental impact of our business. 1,263 5,697 PROGRESS ON FIVE-YEAR GOALS, 2013-2016: CARBON* ELECTRICITY* volunteers hours Reduced our greenhouse Reduced our gas emissions per consumption per employee by 31%, employee by 2%, exceeding our expanded moving toward our 650 organizations 91 % of employees feel good 2018 goal of 30% 2018 goal of 10% WASTE HAZARDOUS supported, about the ways we contribute 68% of our waste CHEMICAL WASTE avoids the landfill, At 53% reduction per including our to the community moving toward our lab employee, we are Matching Gifts Program — Great Places to Work® Survey 2018 goal of 90% just short of our 2018 goal of 60% *Carbon and Electricity baselines are reported based on the original Carbon Disclosure Project (CDP) reporting year; 2013 information noted above corresponds to June 2013 — May 2014 reporting year. < < M ENMENU U > > 2016 ANNUAL REPORT 25


  • Page 26

    SUPPORTING PATIENT COMMUNITIES Regeneron is committed to supporting patients with serious diseases and ensuring that patients are able to access the medicines they need. BRINGING ATTENTION TO A DEBILITATING DISEASE OUR MEDICINES: The Understand AD national initiative aims to increase awareness and understanding of atopic dermatitis (AD), in ENSURING ACCESS partnership with the National Eczema Association (NEA) and the Dermatology Nurses’ Association (DNA). The most common form of eczema, AD is a chronic inflammatory disease with symptoms often appearing as a rash AND EDUCATION on the skin. The initiative offers a glimpse into the daily struggle of life with AD and connects people to helpful resources such as the NEA. EDUCATION & AWARENESS FOR CHOLESTEROL MANAGEMENT In 2016, Regeneron and Sanofi committed to support the American Heart Association’s cholesterol education program, Check.Change.Control.Cholesterol, which aims to drive millions of Americans to better cholesterol management. The three-year program will engage patients, caregivers and healthcare practitioners, and provide valuable educational resources to communities across the country. PARTNERING TO FIGHT A RARE DISEASE Fibrodysplasia ossificans progressiva (FOP) is an exceedingly rare disease in which bone forms in the muscle and connective tissue. Over time, people living with FOP gradually lose the ability to move and even breathe as their rib cage loses flexibility. When Regeneron discovered that the protein Activin-A played a role in triggering FOP, we made it a priority to reach out to the small but strong FOP community to understand their daily struggles and treatment expectations. Since then, organizations such as the International Fibrodysplasia Ossificans Progressiva Association (IFOPA) and the National Organization for Rare Disorders (NORD) have been integral to informing the development of our investigational candidate REGN2477 and to helping us keep patient needs front and center in our efforts. We’ve also given back to the FOP community with grants and by sharing our genetically modified FOP mouse model with other scientists to advance basic and translational research. Through these mutually supportive relationships, we have come together with the FOP community to fight this devastating disease. < < M ENMENU U > > 2016 ANNUAL REPORT 26


  • Page 27

    NURTURING OUR HIGH-ENGAGEMENT, HIGH-INTEGRITY CULTURE Creating a one-of-a-kind culture of collaboration and holding ourselves to the highest ethical standards are essential to our company vision. We believe in the power of original thinking. As a company built on breakthrough ideas, we foster collaboration, curiosity, openness, and inspiration from within — and we do it with an unwavering #1 Biopharma Employer, commitment to ethics. Each of us plays an active role in transforming people’s lives through our work, and we pursue this goal with passion and vigor, never losing focus on integrity. Regeneron’s people Science make us who we are, and we are truly more than a company — we’re a community. 3RD Most Innovative Company, Forbes 93 % of employees say “I’m proud to tell others I work here” 3RD CONSECUTIVE YEAR 100 Best Companies to Work For, – Great Places to Work® Survey Fortune WORLD’S BEST “Our culture is rooted in doing the right thing, even when it may not World’s Best CEOs, Barron’s be easy. In the long run, acting ethically and with integrity is essential to the safety of our patients and to our business success.” R+D — Leonard S. Schleifer, MD, PhD, President and CEO Team of the Year, Scrip < < M ENMENU U > > 2016 ANNUAL REPORT 27


  • Page 28

    FORWARD-LOOKING STATEMENTS This Annual Report includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron’s products, product candidates, and research and clinical programs now underway or planned, including without limitation EYLEA ® (aflibercept) Injection, PRALUENT® (alirocumab) Injection, DUPIXENT® (dupilumab) Injection, KEVZARA ® (sarilumab) Injection, fasinumab, suptavumab (REGN2222), REGN2810 (antibody to programmed cell death protein 1), Regeneron’s earlier-stage product candidates, Regeneron’s immuno-oncology program, and the use of human genetics in Regeneron’s research process; the extent to which the results from Regeneron’s research programs or preclinical testing may lead to advancement of product candidates to clinical trials or therapeutic applications; unforeseen safety issues resulting from the administration of products and product candidates in patients, including serious complications or side effects in connection with the use of Regeneron’s product candidates in clinical trials; the likelihood and timing of possible regulatory approval and commercial launch of Regeneron’s late-stage product candidates and new indications for marketed products, including without limitation EYLEA, PRALUENT, DUPIXENT, KEVZARA, fasinumab, suptavumab, and REGN2810; risks associated with intellectual property of other parties and pending or future litigation relating thereto, including without limitation the patent litigation relating to Praluent, the permanent injunction granted by the United States District Court for the District of Delaware that, if upheld on appeal, would prohibit Regeneron and Sanofi from marketing, selling, or commercially manufacturing Praluent in the United States, the outcome of any appeals regarding such injunction, the ultimate outcome of such litigation, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition; the likelihood and timing of achieving any of the anticipated milestones described in this Annual Report; ongoing regulatory obligations and oversight impacting Regeneron’s marketed products (such as EYLEA, PRALUENT, and DUPIXENT), research and clinical programs, and business, including those relating to patient privacy; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s products and product candidates; competing drugs and product candidates that may be superior to Regeneron’s products and product candidates; uncertainty of market acceptance and commercial success of Regeneron’s products and product candidates; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; the ability of Regeneron’s collaborators, suppliers, or other third parties to perform filling, finishing, packaging, labelling, distribution, and other steps related to Regeneron’s products and product candidates; coverage and reimbursement determinations by third-party payers, including Medicare and Medicaid; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its sales or other financial projections or guidance and changes to the assumptions underlying those projections or guidance; and the potential for any license or collaboration agreement, including Regeneron’s agreements with Sanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or their respective affiliated companies, as applicable), to be cancelled or terminated without any further product success. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the fiscal year ended December 31, 2016, including in the section thereof captioned “Item 1A. Risk Factors.” Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise. < < M ENMENU U > > 2016 ANNUAL REPORT 28


  • Page 29

    CORPORATE INFORMATION Common Stock and Related Matters Our Common Stock is traded on The NASDAQ Global Select Market under the symbol “REGN.” Our Class A Stock is not publicly quoted or traded. The following table sets forth, for the periods indicated, the range of high and low sales prices for the Common Stock as reported by The NASDAQ Global Select Market. 2014 HIGH LOW 2015 HIGH LOW 2016 HIGH LOW First Quarter $352.49 $262.97 First Quarter $495.50 $393.00 First Quarter $532.91 $348.96 Second Quarter $320.00 $269.50 Second Quarter $544.00 $433.47 Second Quarter $433.93 $329.09 Third Quarter $369.31 $285.06 Third Quarter $605.93 $435.52 Third Quarter $443.99 $348.43 Fourth Quarter $437.64 $320.06 Fourth Quarter $592.59 $448.10 Fourth Quarter $452.96 $325.35 As of April 13, 2017, there were 193 shareholders of record of our Common Stock and 18 shareholders of record of our Class A Stock. The closing sales price for the Common Stock on that date was $370.37. We have never paid cash dividends and do not anticipate paying any in the foreseeable future. SEC Form 10-K 2017 Annual Shareholder Meeting A copy of our 2016 Annual Report on Form 10-K filed with the Securities and Exchange The 2017 Annual Shareholder Meeting will be held on Friday, Commission (which accompanies and forms part of this 2016 Annual Report to Shareholders) June 9, 2017, at 10:30 a.m. at the Westchester Marriott Hotel, is available without charge from the Regeneron Investor Relations Department. 670 White Plains Road, Tarrytown, New York 10591. Shareholders’ Inquiries Inquiries relating to stock transfer or lost certificates and notices of changes of address should be directed to our Transfer Agent, American Stock Transfer & Trust Co., 6201 15th Avenue, Brooklyn, New York 11219, (800) 937-5449, . General information regarding the Company, recent press releases and SEC filings are available on our website at or can be obtained by contacting our Investor Relations Department at (914) 847-7741. Corporate Office Transfer Agent and Registrar Independent Registered Public Accounting Firm 777 Old Saw Mill River Road American Stock Transfer & Trust Co. PricewaterhouseCoopers LLP Tarrytown, New York 10591-6707 6201 15th Avenue (914) 847-7400 Brooklyn, New York 11219 REGENERON ®, Science to Medicine ® and the following are registered trademarks of Regeneron Pharmaceuticals, Inc.: ARCALYST®, EYLEA ®, VelociGene®, and VelocImmune®. Praluent®, Dupixent®, and Kevzara® are registered trademarks of Sanofi. < < M ENMENU U > > 2016 ANNUAL REPORT 29


  • Page 30

    REFERENCES 1. Osteoarthritis Fact Sheet. CDC Website. Available at: . Accessed March 30, 2017. 2. Semanik P, Chang RW, Dunlop DD. PMR. 2012;4(50):S37–S44. 3. National Center for Health Statistics. Health, United States, 2015. Hyattsville, MD, 2016. < < M ENMENU U 2016 ANNUAL REPORT 30


  • Page 31

  • View More

Get the full picture and Receive alerts on lawsuits, news articles, publications and more!